Evidence map›Paper›PMID 35641478›Full record

ArticleSignal transduction and targeted therapy2022

BOD1 regulates the cerebellar IV/V lobe-fastigial nucleus circuit associated with motor coordination.

Xiu-Xiu Liu, Xing-Hui Chen, Zhi-Wei Zheng, Qin Jiang, Chen Li, Lin Yang, Xiang Chen, Xing-Feng Mao, Hao-Yang Yuan, Li-Li Feng and 7 more

Open access · goldAbstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Upregulated inwardly rectifying KJournal of biomedical research · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Xiu-Xiu LiuKey Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing Medical University, 211166, Nanjing, China.
Xing-Hui ChenDepartment of Physiology, School of Basic Medical Sciences, Nanjing Medical University, 211166, Nanjing, China.
Zhi-Wei ZhengDepartment of Physiology, School of Basic Medical Sciences, Nanjing Medical University, 211166, Nanjing, China.
Qin JiangDepartment of Physiology, School of Basic Medical Sciences, Nanjing Medical University, 211166, Nanjing, China.
Chen LiKey Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing Medical University, 211166, Nanjing, China.
Lin YangDepartment of Physiology, School of Basic Medical Sciences, Nanjing Medical University, 211166, Nanjing, China.
Xiang ChenKey Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing Medical University, 211166, Nanjing, China.
Xing-Feng MaoKey Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing Medical University, 211166, Nanjing, China.
Hao-Yang YuanDepartment of Physiology, School of Basic Medical Sciences, Nanjing Medical University, 211166, Nanjing, China.ORCID 0000-0002-4059-3184
Li-Li FengKey Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing Medical University, 211166, Nanjing, China.
Quan JiangInstitute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
Wei-Xing ShiDepartment of Pharmaceutical and Administrative Sciences, Loma Linda University School of Pharmacy, Loma Linda, CA, 92350, USA.
Takuya SasakiDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.
Kohji FukunagaDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.
Zhong ChenInstitute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.ORCID 0000-0003-4755-9357
Feng HanKey Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing Medical University, 211166, Nanjing, China. fenghan169@njmu.edu.cn.
Ying-Mei LuDepartment of Physiology, School of Basic Medical Sciences, Nanjing Medical University, 211166, Nanjing, China. lufx@njmu.edu.cn.
Nanjing Medical University · CNZhejiang University · CNTohoku University · JPChina Pharmaceutical University · CNLoma Linda University · USNanjing Brain Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebellar ataxias are characterized by a progressive decline in motor coordination, but the specific output circuits and underlying pathological mechanism remain poorly understood. Through cell-type-specific manipulations, we discovered a novel GABAergic Purkinje cell (PC) circuit in the cerebellar IV/V lobe that projected to CaMKIIα

Indexed as

Cerebellar NucleiPurkinje CellsAnimalsAtaxiaMiceNeurons

Identifiers

PMID35641478
PMCPMC9156688
OpenAlexW4282931888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.